|
[posting]56547313[/posting]Volumen (obwohl auch das bei AXSM noch relativ niedrig ist) mit kaum Preisveränderung muss nicht unbedingt was schlechtes sein solange Management und Institutionelle nicht verkaufen ist alles noch im grünen bereich . AXSM could be the next 4 - 6 bagger biotechstock https://www.tradingview.com/chart/AXSM/di8zNJvb-AXSM-could-b… Axsome Therapeutics Inc (AXSM) Shares Bought by JPMorgan Chase & Co....Posted by Andrew Steele on Dec 27th, 2017 https://stocknewstimes.com/2017/12/27/axsome-therapeutics-in… JPMorgan Chase & Co. increased its position in Axsome Therapeutics Inc (NASDAQ:AXSM) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,459,117 shares of the company’s stock after buying an additional 23,229 shares during the period. JPMorgan Chase & Co. owned 6.18% of Axsome Therapeutics worth $8,026,000 at the end of the most recent quarter. |
|
| aus der Diskussion: | AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 |
| Autor (Datum des Eintrages): | Biohero (28.12.17 16:42:10) |
| Beitrag: | 149 von 268 (ID:56560204) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |